Stage I of Phase II study assessing efficacy, safety and tolerability of barasertib (AZD1152) versus LDAC in elderly AML patients

समान संसाधन

• Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML
  द्वारा: Kantarjian, Hagop M, और अन्य
  प्रकाशित: (2013)
• Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia
  द्वारा: Löwenberg, Bob, और अन्य
  प्रकाशित: (2011)
• Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia
  द्वारा: Dennis, Mike, और अन्य
  प्रकाशित: (2012)
• Barasertib (AZD1152), a small molecule Aurora B inhibitor, inhibits the growth of SCLC cell lines in vitro and in vivo
  द्वारा: Helfrich, Barbara A, और अन्य
  प्रकाशित: (2016)
• AZD1152 rapidly and negatively affects the growth and survival of Human AML cells in vitro and in vivo
  द्वारा: Oke, Adedayo, और अन्य
  प्रकाशित: (2009)